ERS Genomics Licenses CRISPR Gene Editing Technology to DefiniGEN to Develop Human Cell Models to Support the Preclinical Development of Therapeutics

4th January 2019

DUBLIN, Ireland, and CAMBRIDGE, UK, November 1, 2018 – ERS Genomics Limited and DefiniGEN Ltd announced today a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. DefiniGEN will combine their best-in-class iPSC (induced Pluripotent Stem Cell) differentiation platform with CRISPR/Cas9 technology to generate a range of innovative preclinical […]